Thursday, 5 November 2026European Markets
ExploreSearch
ViaNews EU
stockMarket

LISGRAFICA Stock Went Up By Over 17% In The Last 5 Sessions

Loading stream...

(VIANEWS) - Shares of LISGRAFICA (PSI: LIG.LS) jumped by a staggering 17.65% in 5 sessions from €0.01 to €0.01 at 17:22 EST on Friday, following the last session's downward trend. PSI is falling 0.5% to €5,986.25, after five successive sessions in a row of gains.

LISGRAFICA's last close was €0.01, 5.56% higher than its 52-week high of €0.01.

About LISGRAFICA

Lisgráfica - Impressão e Artes Gráficas, S.A. provides printing services in Portugal. It prints magazines, newspapers, supplements, catalogs, brochures, and telephone directories. The company was incorporated in 1973 and is headquartered in Agualva-Cacém, Portugal. Lisgrafica-Impressao e Artes Graficas is a subsidiary of Rasográfica - Comércio e Serviços Gráficos, S.A.

Earnings Per Share

As for profitability, LISGRAFICA has a trailing twelve months EPS of €-0.026.

More news about LISGRAFICA (LIG.LS).

Categories

stockMarket

Tags

Stock PriceMarket Session NowLIG.LSStock Market NowLISGRAFICAPrice UpMarket SessionStock Price UpStock MarketStock
What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Oncology Data Season and Biotech Capital Allocation: ESMO Readouts, Ivonescimab PDUFA, and Diverging Corporate Moves
Late-2026 biotech is driven by a dense catalyst calendar. ESMO 2026 delivers data from ivonescimab, Enhertu, R-DXd and bemarituzumab, and the FDA has set a 14 Nov PDUFA date for the ivonescimab BLA. Capital allocation is diverging. Krystal Biotech authorized a $400M buyback while lowering FY2026 spend guidance and pushing milestones into 2027. Spago is moving to delist from Nasdaq First North. The facts are clinical and corporate events, not AI or fintech, so the finance angle is limited to capital markets (buybacks, guidance, delistings, regulatory timelines).
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,995
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,995 facts checked against source5,549 source documents archived
Query this data → isubstrate.com